Press Releases
2024
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2023
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2022
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2021
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2020
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2019
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
2018 & Prior
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Media
Several Players Begin 2022 with New Partnerships in Place
BioSpace
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
BioSpace
Epigenetic Therapies Start Operating Outside the Lines
Genetic Engineering and Biotechnology News
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development
AdAPT-001 Mechanism of Action
AdAPT-001 doesn’t just create a cancer-targeted infection, it produces a proprietary TGFβ “trap”...
Conferences
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
According to writer, Dorothy Parker, you can’t teach an old dogma new tricks. In oncology, the dogma is not to rechallenge tumors with previously tried therapies. If RRx-001 and AdAPT-001 can manage to overturn this dogma, we'd call that karma. Read here: